[
  {
    "ts": null,
    "headline": "Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?",
    "summary": "OPKO Health recently reported third-quarter earnings with revenue of US$151.67 million and net income of US$21.63 million, surpassing analyst expectations, and announced a collaboration with Regeneron Pharmaceuticals potentially valued at over US$1 billion. The company also finalized the US$225 million sale of its BioReference Health oncology assets to Labcorp and received FDA approval for broader use of its 4Kscore® Test, marking significant changes in its business focus and regulatory...",
    "url": "https://finnhub.io/api/news?id=d489126718a1ebe928b5602c102d1986423cb899a015dab230dd28b05f0b58b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761938310,
      "headline": "Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?",
      "id": 137294989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "OPKO Health recently reported third-quarter earnings with revenue of US$151.67 million and net income of US$21.63 million, surpassing analyst expectations, and announced a collaboration with Regeneron Pharmaceuticals potentially valued at over US$1 billion. The company also finalized the US$225 million sale of its BioReference Health oncology assets to Labcorp and received FDA approval for broader use of its 4Kscore® Test, marking significant changes in its business focus and regulatory...",
      "url": "https://finnhub.io/api/news?id=d489126718a1ebe928b5602c102d1986423cb899a015dab230dd28b05f0b58b6"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win",
    "summary": "While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.",
    "url": "https://finnhub.io/api/news?id=9875190ef153cf6d3f100b95b6124cee15b8e9e8541a323748b4a5d460929efe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761914265,
      "headline": "AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win",
      "id": 137277455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.",
      "url": "https://finnhub.io/api/news?id=9875190ef153cf6d3f100b95b6124cee15b8e9e8541a323748b4a5d460929efe"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award",
    "summary": "Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Produ",
    "url": "https://finnhub.io/api/news?id=140117a3d7d01091f423d2ea5bd882fac8635abb6916bf6d93377609e395b196",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761908400,
      "headline": "Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award",
      "id": 137277456,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Produ",
      "url": "https://finnhub.io/api/news?id=140117a3d7d01091f423d2ea5bd882fac8635abb6916bf6d93377609e395b196"
    }
  },
  {
    "ts": null,
    "headline": "JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential",
    "summary": "JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. (\"Regeneron\"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora",
    "url": "https://finnhub.io/api/news?id=ad4148311f515a0b628ca0b9bafb017404e6b85da5f9d7f6d58139831f2dd7ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761903480,
      "headline": "JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential",
      "id": 137277457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. (\"Regeneron\"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora",
      "url": "https://finnhub.io/api/news?id=ad4148311f515a0b628ca0b9bafb017404e6b85da5f9d7f6d58139831f2dd7ae"
    }
  },
  {
    "ts": null,
    "headline": "Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals",
    "summary": "Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest. […]",
    "url": "https://finnhub.io/api/news?id=6a0bc4a44ca3614d9d1ec26a506da92ac4b1e0db64725aa0a9764e7ae3f579f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761881365,
      "headline": "Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals",
      "id": 137275235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest. […]",
      "url": "https://finnhub.io/api/news?id=6a0bc4a44ca3614d9d1ec26a506da92ac4b1e0db64725aa0a9764e7ae3f579f2"
    }
  }
]